We Need Your Help! PDF Print E-mail
Tuesday, 09 March 2010 20:51
Today, the Scleroderma Care Foundation embarks upon a mission of vital importance, and we are counting on your help.

One of our dearest Scleroderma patients and friend, Agnes Basil-James, is on the verge of Renal or kidney failure and we are seeking out a qualified kidney donor. Currently, her kidneys are operating at around 2% efficiency and she undergoes dialysis treatment several times per week. Agnes is also the longest known survivor of Scleroderma in Trinidad & Tobago, having been diagnosed with the disease in 1986, some 24 years ago.

As many are aware, Systemic Scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal, and other complications. Renal involvement in Scleroderma is typically considered a poor prognostic factor and frequent cause of death. Approximately 5-10% of all Scleroderma patients develop renal crisis at some point in the course of their disease, and is most common in diffuse coetaneous Scleroderma, often associated with antibodies against RNA polymerase (in 59% of cases). Many proceed to dialysis, although this can be stopped within three years in about a third of all cases.

Our programme, for as long as it takes, would seek to find an applicable donor for Agnes. From today, we would be featuring several articles on our site, on the nature and function of the kidneys, and associated renal involvement in Scleroderma. We also seek to provide some assistive and invaluable information on how you can become an organ donor yourself, along with tips for taking much better care of your very own kidneys.

It is our very sincere hope that someone out there, with blood group O, reading this, would be willing to come forward and assist Agnes. We would also like to encourage everyone reading this to please share with family, friends, co-workers, and associates, as our request for assistance may just reach the right person.

Agnes has been so kind as to share with us all, her story, which you can read here. For more information, please do feel free to contact us via email here, or phone at 756-3930 or 685-3213. Also, join us on Facebook or Twitter, where we would post updates as we progress.

Thank you.

Adelwyn Holder
President, Scleroderma Care Foundation
 
More articles :

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» Autoimmune Disease Symptoms To Look Out For

We have understood for  a long time that the detection and subsequent diagnoses of autoimmune diseases are difficult. However, there are key rheumatic and physical indicators such as joint pain and fatigue, fevers, increasing skin conditions,...

» HLA Class II Haplotype and Autoantibody Associations in Children

L. R. Wedderburn; N. J. McHugh; H. Chinoy; R. G. Cooper; F. Salway; W. E. R. Ollier; L. J. McCann; H. Varsani; J. Dunphy; J.North; J. E. DavidsonPosted: 12/19/2007; Rheumatology. 2007;46(12):1786-1791. © 2007 Oxford University PressObjectives: To...

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» Rare Diseases Day

Febuary 28th, 2010 was Rare Diseases Day, and it was marked with a variety of events and activities all over the world - as well as with plenty of citizen media and online participation. The goal was to raise awareness about so-called. These are...